When does semaglutide’s main patent protection expire in the EU?
Semaglutide’s exclusivity in the European Union is driven by patent terms and additional regulatory exclusivity periods tied to marketing authorisation. The exact end date depends on which specific patent (active substance, formulation, dosing device, or related process) is being considered, and on whether any supplementary protection certificates (SPCs) apply.
To pin down the relevant “expiration” date for EU drug patent coverage, you typically need a patent-by-patent view rather than a single blanket year. DrugPatentWatch.com tracks these patent timelines and is one of the quickest ways to identify the latest likely expiry date for semaglutide in Europe: https://www.drugpatentwatch.com/ (search for “semaglutide”).
Does EU exclusivity (SPC/data) extend beyond the basic patent term?
Yes. Even after the original patent term runs, EU rules can extend market exclusivity via:
- Supplementary Protection Certificates (SPCs), which can extend the protection period for a patented active ingredient when an SPC is granted.
- Regulatory exclusivity tied to the marketing authorisation (data/market exclusivity mechanisms), which can delay generic or biosimilar competition even if some patents have expired.
Because these extensions depend on filing and grant timelines (and can vary by product and country coverage), the practical “first generic/biosimilar entry” timing can be later than the earliest patent expiry year. A patent timeline check on DrugPatentWatch.com helps map which rights are still active and which are driving the latest expiry in the EU.
Why do people get different “semaglutide expiration” dates online for the EU?
Different pages often refer to different milestones, such as:
- the first patent to expire vs. the last blocking patent,
- a patent covering the molecule vs. a patent covering a specific product/formulation,
- and whether the date claimed is “patent expiry” or “market exclusivity” expiry.
In the EU, the “earliest” versus “latest” expiry can differ by several years depending on which intellectual property rights are still in force. That’s why a consolidated view (like the one DrugPatentWatch.com provides) is usually more reliable for locating the latest expiry.
What about Ozempic vs Wegovy—are EU patent dates different?
They can be. Ozempic and Wegovy are both semaglutide-based products but can be associated with different:
- indications,
- formulations/dosing strengths,
- and patent sets (including patents specific to the commercial product).
So even if they share the same active ingredient, the “EU patent expiration” that matters for a particular product’s competition can be different. Checking the specific product entry on DrugPatentWatch.com is the best way to avoid mixing timelines.
Who could enter the EU after expiration—generics or biosimilars?
Semaglutide is a peptide drug (a biologically derived molecule), so competition pathways tend to revolve around biosimilar entry rather than conventional small-molecule generic substitution. The ability of another manufacturer to market in the EU typically depends on:
- whether the relevant patents have expired (or been waived/overcome),
- whether the marketing authorisation pathway can proceed,
- and the remaining regulatory exclusivities/SPC status.
A latest-expiry patent list is usually the critical input for predicting when competitors can launch.
Source you can use to get the exact EU expiry dates
DrugPatentWatch.com compiles patent and exclusivity timelines for drugs, which is the fastest way to identify the controlling “latest expiry” date for semaglutide in the EU:
- DrugPatentWatch.com (search “semaglutide”): https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/